ATE276261T1 - Tetrahydrochinazolin-2,4-dione zur verwendung als therapeutische medikamente - Google Patents

Tetrahydrochinazolin-2,4-dione zur verwendung als therapeutische medikamente

Info

Publication number
ATE276261T1
ATE276261T1 AT00307433T AT00307433T ATE276261T1 AT E276261 T1 ATE276261 T1 AT E276261T1 AT 00307433 T AT00307433 T AT 00307433T AT 00307433 T AT00307433 T AT 00307433T AT E276261 T1 ATE276261 T1 AT E276261T1
Authority
AT
Austria
Prior art keywords
alkyl
tetrahydroquinazoline
nhc
inhibition
methods
Prior art date
Application number
AT00307433T
Other languages
English (en)
Inventor
Todd William Butler
Anton Franz Josef Fliri
Randall James Gallaschun
Brian Patrick Jones
John Anthony Ragan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE276261T1 publication Critical patent/ATE276261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00307433T 1999-08-31 2000-08-30 Tetrahydrochinazolin-2,4-dione zur verwendung als therapeutische medikamente ATE276261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15172599P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
ATE276261T1 true ATE276261T1 (de) 2004-10-15

Family

ID=22539996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00307433T ATE276261T1 (de) 1999-08-31 2000-08-30 Tetrahydrochinazolin-2,4-dione zur verwendung als therapeutische medikamente

Country Status (8)

Country Link
US (2) US6521630B1 (de)
EP (1) EP1083178B1 (de)
JP (2) JP3285343B2 (de)
AT (1) ATE276261T1 (de)
DE (1) DE60013716T2 (de)
DK (1) DK1083178T3 (de)
ES (1) ES2226726T3 (de)
PT (1) PT1083178E (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521630B1 (en) * 1999-08-31 2003-02-18 Pfizer Inc. Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof
US6552015B2 (en) 2000-08-03 2003-04-22 Pfizer Inc. Azabicycloalkane derivatives and therapeutic uses thereof
US6780860B2 (en) 2001-04-26 2004-08-24 Wyeth Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists
JPWO2004060400A1 (ja) * 2003-01-06 2006-05-11 那波 宏之 上皮成長因子受容体を分子標的とする抗精神病薬
US7632950B2 (en) * 2003-08-18 2009-12-15 Fujifilm Finechemicals Co., Ltd Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
US8344512B2 (en) * 2009-08-20 2013-01-01 International Business Machines Corporation Three-dimensional silicon interposer for low voltage low power systems
US9546151B2 (en) 2014-07-31 2017-01-17 Oregon Health & Science University VMAT inhibitory compounds
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
JPS4822715B1 (de) * 1970-12-28 1973-07-07
US3919425A (en) 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
US3726979A (en) 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
US3879393A (en) 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
CA1246074A (en) 1984-12-05 1988-12-06 Albertus H.M.T. Van Heertum Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4684654A (en) 1985-08-14 1987-08-04 American Cyanamid Company 3-heteroalkyl-2,4-quinzaolinediones
JPS646269A (en) 1987-03-11 1989-01-10 Yoshitomi Pharmaceutical Quinoline derivative
IL90858A (en) 1988-07-07 1994-08-26 Rhone Poulenc Sante Derivatives of (AZA) naphthalensultam, their preparation and compositions containing them
US5296487A (en) 1990-01-02 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives and their preparation
ATE126796T1 (de) 1990-01-02 1995-09-15 Fujisawa Pharmaceutical Co Quinazolinderivate und ihre herstellung.
IE913473A1 (en) 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
WO1993005035A1 (en) 1991-09-06 1993-03-18 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives and their preparation
US5296438A (en) * 1992-09-29 1994-03-22 The United States Of America As Represented By The United States Department Of Energy Dimensionally stable metallic hydride composition
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
AU9002598A (en) * 1997-09-16 1999-04-05 Takeda Chemical Industries Ltd. Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6521630B1 (en) 1999-08-31 2003-02-18 Pfizer Inc. Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof

Also Published As

Publication number Publication date
JP2001114778A (ja) 2001-04-24
JP2002212161A (ja) 2002-07-31
EP1083178B1 (de) 2004-09-15
JP3285343B2 (ja) 2002-05-27
US20030109516A1 (en) 2003-06-12
EP1083178A1 (de) 2001-03-14
JP3727569B2 (ja) 2005-12-14
DE60013716T2 (de) 2005-11-24
DK1083178T3 (da) 2005-01-24
US6521630B1 (en) 2003-02-18
DE60013716D1 (de) 2004-10-21
ES2226726T3 (es) 2005-04-01
PT1083178E (pt) 2004-12-31

Similar Documents

Publication Publication Date Title
DK2297120T3 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of Alzheimer's disease
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
MXPA04004982A (es) Derivados de benzotiazol.
KR890008137A (ko) 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
SI20269A (sl) Derivati acil-piperazinil-pirimidinov, njihova priprava in uporaba kot zdravila
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
ATE297929T1 (de) Azabicycloalkan-derivate zur verwendung als inhibitoren der serotonin-wiederaufnahme und als 5ht2a antagonisten
DE60013716D1 (de) Tetrahydrochinazolin-2,4-dione zur Verwendung als therapeutische Medikamente
US6380229B1 (en) 2-(N-cyanoimino)thiazolidin-4-one derivatives
JPH0967367A (ja) チオピラン誘導体
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
DE60102106D1 (de) Diazacyclooctanverbindungen und ihre therapeutische Verwendung
KR100366962B1 (ko) 벤조티아진유도체
FR2675504A1 (fr) Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique.
ATE388945T1 (de) Benzoxazolderivate und deren verwendung als adenosinrezeptorliganden
US4656265A (en) Cyclic prodrugs of antiinflammatory oxicams
DE69110219D1 (de) 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
US5217968A (en) N-alkylbenzo(b)thieno [3,2-b]oxazin-2,4-diones
JPH01113377A (ja) ピペラジン化合物
DE69626624D1 (de) Medikamente gegen trhombocytopenie
JP4880348B2 (ja) アズレン誘導体及びそれを有効成分とする血清コレステロール低下剤
ATE108444T1 (de) 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1083178

Country of ref document: EP

REN Ceased due to non-payment of the annual fee